Evidence map›Paper›PMID 40009768›Full record

ArticleCancer research2025

CXCL10 Secreted by Pericytes Mediates TNFα-Induced Vascular Leakage in Tumors and Enhances Extravasation of Nanoparticle-Based Chemotherapeutics.

Ann L B Seynhaeve, Hui Liu, Marjolein I Priester, Mike Valentijn, Conny van Holten-Neelen, Rutger W W Brouwer, Mandy van Brakel, Willem A Dik, Wilfred F J van IJcken, Reno Debets and 2 more

Abstract read
In one paragraph

Article in Cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ann L B SeynhaevePrecision Medicine in Oncology, Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-7389-3597
Hui LiuPrecision Medicine in Oncology, Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0009-0003-5337-0208
Marjolein I PriesterPrecision Medicine in Oncology, Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-6201-5951
Mike ValentijnPrecision Medicine in Oncology, Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0009-0003-3564-1721
Conny van Holten-NeelenLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0009-0009-9853-8346
Rutger W W BrouwerCenter for Biomics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-7524-6230
Mandy van BrakelLaboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-9679-1094
Willem A DikLaboratory Medical Immunology, Department of Immunology, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-5235-3156
Wilfred F J van IJckenCenter for Biomics, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-0421-8301
Reno DebetsLaboratory of Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-3649-807X
Andrew P StubbsDepartment of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0001-9817-9982
Timo L M Ten HagenPrecision Medicine in Oncology, Department of Pathology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-0955-7740

Funding

KWF Kankerbestrijding (DCS) DDHK-2000-2224Stichting Erasmus Heelkundig kankeronderzoekVereniging Trustfonds Erasmus Universiteit Rotterdam (Erasmus Trustfonds)
6 · The paper itself

Abstract

TNFα induces vascular permeability and plays an important role in inflammation. In addition, TNFα-induced vascular leakage is involved in the increased extravasation of nanoparticle-formulated chemotherapeutic drugs, improving drug delivery and subsequent tumor response. In this study, we uncovered a positive correlation between the presence of pericytes in the tumor-associated vasculature and TNFα-induced leakage and drug delivery, especially when drugs were encapsulated in nanoparticles. RNA sequencing and pathway analysis identified high expression of C-X-C motif chemokine ligand 10 (CXCL10) in TNFα-stimulated pericytes. In addition, TNFα increased CXCL10 protein production by pericytes in vitro. In animal studies, tumor types with vessels with high pericyte coverage showed enhanced permeability and extravasation of drugs encapsulated in nanoparticles following treatment with TNFα, which could be blocked with a CXCL10-neutralizing antibody. In contrast, tumors harboring vessels with low pericyte numbers did not display increased drug extravasation in response to TNFα. Lack of pericyte coverage could be compensated by coadministration of CXCL10. These findings reveal a mechanism by which TNFα induces CXCL10 release from pericytes, resulting in increased endothelial permeability, vascular leakage, and drug delivery. Significance: TNFα stimulates tumor-associated pericytes to produce CXCL10 that mediates vascular leakage and assists in the intratumoral delivery of nanoparticle-encapsulated chemotherapeutic drugs.

Indexed as

Antineoplastic AgentsCapillary PermeabilityChemokine CXCL10Extravasation of Diagnostic and Therapeutic MaterialsNanoparticlesNeoplasmsPericytesTumor Necrosis Factor-alphaAnimalsCell Line, TumorFemaleHumansMiceAntineoplastic AgentsChemokine CXCL10CXCL10 protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID40009768
PMCPMC12046328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.